Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration.

ABSTRACT:

Background/aims

To study the initial characteristics and response to intravitreal ranibizumab (IVR) treatment of age-related macular degeneration (AMD).

Methods

We reviewed the clinical records of 141 eyes in 141 AMD patients who received monthly IVR for 3 months and thereafter pro re nata (PRN) injections for 9 months as the first treatment for AMD. Patients whose best corrected visual acuity (BCVA) worsened at month 12, and those with increased exudative fundus findings after IVR or an increased central retinal thickness of more than 100 μm at month 12, were considered to be non-responders as judged by BCVA and fundus findings, respectively. Non-responders' initial characteristics were analysed using logistic regression models.

Results

14.9% of eyes were non-respond

SUBMITTER: Suzuki M 

PROVIDER: S-EPMC4145467 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature